Insulin Release, Glucose-induced (Agonist & Antagonist), Panlabs
OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
Insulin primary role is to maintain blood glucose levels in the normal range. Secretion of Insulin by pancreatic B cells is controlled by hormones, nutrients and neurotransmitters however the primary stimulus for insulin secretion is the beta-cell response to changes in ambient glucose. Insulin secretion is triggered by the elevation of ATP in the pancreatic b cells caused by glucose metabolism. This ATP/ADP ratio increase will close the KATP channel leading to cell membrane depolarization and increase in cytosolic Ca++.
No. of Assays on Panel:
2
Assays on Panel:
Family
Endocrine System
Name
Insulin Release, Glucose-induced (Agonist), Panlabs
Item
331500-0
Protein
Organism
Hamster
Assay Sub Type
Cell Based
Family
Endocrine System
Name
Insulin Release, Glucose-induced (Antagonist), Panlabs
Item
331500-1
Protein
Organism
Hamster
Assay Sub Type
Cell Based
Family:
Endocrine System
Sub Family:
Insulin
Class:
Mediator Release
Organism:
Hamster
Construct Details:
Endogenous
Cell Type:
HIT-T15
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Functional Mode:
Agonist & Antagonist
Detection Method:
TR-FRET
Measured Response:
Fluorescence
Testing Information
Procedure Summary:
Hamster HIT-T15 cells are used. Test compound and/or vehicle is incubated with the cells (1 Χ 10^6 /ml) in glucose buffer of insulin kit for 90 minutes at 37°C. Test compound-induced increase of insulin by 50 percent or more (≥50%) relative to the 100 mM glucose response indicates possible agonist activity. Test compound-induced inhibition of 10 mM glucose increase of insulin by 50 percent or more (≥50%) indicates antagonist activity.
Incubation:
1.5 hr at 37°C
Control Inhibitor:
Somatostatin-14
Control Activator:
D-Glucose
Criteria For Significance:
≥ 50% Increase in insulin release relative to glucose response, ≥ 50% Inhibition of glucose-induced insulin release
Test Concentration / Dose:
Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM
Test Sample Requirements:
75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)
Minimum Order Quantity:
16
Turnaround Time
Standard:
20 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Metabolic Diseases
Adverse / Beneficial Action:
Increase in systemic insulin will lower glucose and this in turn will turn down the insulin secretion from the pancreatic cells.
Additional Information
Brand:
Panlabs
Testing Location:
Taiwan - Taipei
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
